SCHEMBL2289458

SCHEMBL2289458

Cn1nc(-c2cccc([N+](=O)[O-])c2)oc1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
ALDH1A1 P00352 4/20 0.56
MAPT P10636 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
PSMB8 P28062 1/20 0.56
MEN1 O00255 1/20 0.51
ELANE P08246 1/20 0.51
KMT2A Q03164 1/20 0.51
KDM4E B2RXH2 1/20 0.49
NOTUM Q6P988 1/20 0.49
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
CA13 Q8N1Q1 1/20 0.48
ABHD16A O95870 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12377820 0.78 NOTUM (0.55) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL2293084 0.77 NOTUM (0.54) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL2285490 0.77 NOTUM (0.54) SMN1; SMN2KMT2AKDM4ENOTUM
SCHEMBL14007387 0.75 NOTUM (0.69) NPC1RAB9AALDH1A1SMN1; SMN2PSMB8
SCHEMBL4607599 0.72 RAB9A (0.73) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL22770156 0.72 NPC1 (0.60) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL10245542 0.72 NPC1 (1.00) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL2291156 0.71 NOTUM (0.68) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL1781484 0.71 PSMB8 (1.00) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL27735322 0.71 RAB9A (0.58) NPC1RAB9AALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2163554-B1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2012-08-01 EP disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
EP-2163554-A1 PYRIMIDODIAZEPINONE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2010-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D NPC1 1132/4885RAB9A 2645/4885ALDH1A1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.